切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2018, Vol. 12 ›› Issue (02) : 179 -182. doi: 10.3877/cma.j.issn.1674-1358.2018.02.016

所属专题： 文献；

临床论著

戊型肝炎患者血清GP73变化特征及意义
蒋煜1, 徐飞2, 胡居龙3, 华文浩2, 李坪3, 魏红山3,†()   
  1. 1. 100015　北京，首都医科大学附属北京地坛医院消化科
    2. 100015　北京，首都医科大学附属北京地坛医院
  • 收稿日期:2017-01-31 出版日期:2018-04-15
  • 通信作者: 魏红山
  • 基金资助:
    国家自然科学基金(No. 81271901); 北京市自然科学基金(No. 7152073); 首都特色临床研究(No. Z141107002514132); 首都医学发展科研基金(No. 2014-2-2171)

Characteristics of serum GP73 for patients with hepatitis E and its clinical significances

Yu Jiang1, Xu Fei2, Julong Hu3, Wenhao Hua2, Ping Li3, Hongshan Wei3,†()   

  1. 2. Clinical Lab, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
    3. Department of Gastroenterology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
  • Received:2017-01-31 Published:2018-04-15
  • Corresponding author: Hongshan Wei
  • About author:
    Corresponding auther: Wei Hongshan, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

蒋煜, 徐飞, 胡居龙, 华文浩, 李坪, 魏红山. 戊型肝炎患者血清GP73变化特征及意义[J/OL]. 中华实验和临床感染病杂志(电子版), 2018, 12(02): 179-182.

Yu Jiang, Xu Fei, Julong Hu, Wenhao Hua, Ping Li, Hongshan Wei. Characteristics of serum GP73 for patients with hepatitis E and its clinical significances[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(02): 179-182.

目的

观察戊型肝炎患者血清GP73变化特征。

方法

分析80例健康体检者（对照组）和66例戊型肝炎患者（观察组）血清GP73水平的变化。

结果

对照组研究对象血清GP73水平为（38.82 ± 15.67）ng/ml，观察组患者血清GP73为（80.06 ± 52.33）ng/ml，较对照组显著升高，差异具有统计学意义（t = 6.785、P < 0.00）；患者血清GP73水平与丙氨酸氨基转移酶（ALT）活性（r = 0.28、P = 0.015）、天门冬氨酸氨基转移酶（AST）活性（r = 0.36、P = 0.002）总胆红素（TBil）水平（r = 0.47、P < 0.001）均呈正相关，而与凝血酶原活动度（PTA）水平呈负相关（r =－0.329、P = 0.004）。

结论

血清GP73显著升高的人群需考虑急性戊型肝炎病毒感染的可能。戊型肝炎患者的血清GP73水平可能与肝功能损伤程度具有一定的相关性。

关键词: 肝炎，戊型, 高尔基体糖蛋白73, 肝功能损伤, 诊断
Objective

To investigate the variable characteristics of serum GP73 for patients with hepatitis E.

Methods

The changes of GP73 level in serum of 80 healthy subjects (control group) and 66 patients with hepatitis E were detected by quantitative enzyme-linked immunosorbent assay.

Results

The median level of serum GP73 for patients with hepatitis E (80.06 ± 52.33 ng/ml) was significantly increased than that of 80 healthy control subjects (38.82 ± 15.67 ng/ml), with significant difference (t = 6.785, P < 0.0001). The level of serum GP73 in patients with hepatitis E had positive correlation with the serum activity of alanine aminotransferase (ALT) (r = 0.28, P = 0.015), aspartate aminotransferase (AST) (r = 0.36, P = 0.002) and the level of serum total bilirubin (TBil) (r = 0.47, P < 0.001). While it had negative correlation with the prothrombin time activity (PTA) (r =-0.329, P = 0.004).

Conclusions

The possibility of acute hepatitis E infection should be considered for those who with significangly elevated serum GP73. Serum GP73 levels in patients with hepatitis E may be correlated with liver damage.

Key words: Hepatitis E, Golgi protein 73, Liver injury, Diagnosis
图1 两组研究对象血清GP73水平
图2 血清GP73水平与肝功能损伤主要指标的相关性
[1]
Kladney RD, Bulla GA, Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene,2000,249(1-2):53-65.
[2]
Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma[J]. J Hepatol,2005,43(6):1007-1012.
[3]
Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut,2010,59(12):1687-1693.
[4]
冯志刚, 岑晓红, 云俊木, 等. GP73在酒精性肝病中的临床意义[J]. 国际检验医学杂志,2015,36(15):2214-2215, 2217.
[5]
魏红山, 康艳芳, 郝晓花, 等. 肝细胞脂肪变对血清糖蛋白GP73水平的影响[J]. 中华实验和临床病毒学杂志,2013,27(4):244-247.
[6]
翟庆玲, 刘燃, 王智强, 等. 自身免疫性肝病患者血清GP73变化特征[J]. 中华实验和临床病毒学杂志,2014,28(4):268-271.
[7]
Wei H, Li B, Zhang R, et al. Serum GP73, a marker for evaluating progression in patients with chronic HBV infections[J]. PLoS One,2013,8(2):e53862.
[8]
Hu L, Yao W, Wang F, et al. GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion[J]. PLoS One,2014,9(3):e90553.
[9]
Maitra A, Thuluvath PJ. GP73 and liver disease: a (Golgi) complex enigma[J]. Am J Gastroenterol,2004,99(6):1096-1098.
[10]
Ozkan H, Erdal H, Tutkak H, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma[J]. Digestion,2011,83(1-2):83-88.
[11]
Wang NY, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation[J]. Asian Pac J Cancer Prev,2014,15(4):1539-1544.
[12]
Özkan H, Erdal H, Tutkak H, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma[J]. Digestion,2010,83(1-2):83-88.
[13]
Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J]. J Gastroenterol,2010,45(12):1272-1282.
[14]
Kristiansen G, Fritzsche FR, Wassermann K, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics[J]. Br J Cancer,2008,99(6):939-948.
[15]
Zhang F, Gu Y, Li X, et al. Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue[J]. Clin Biochem,2010,43(12):983-991.
[16]
Wright LM, Huster D, Lutsenko S, et al. Hepatocyte GP73 expression in Wilson disease[J]. J Hepatol,2009,51(3):557-564.
[17]
Wei H, Hao X, Li B, et al. GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy[J]. Mol Biol Rep,2013,40(11):6397-6405.
[18]
Bao YX, Cao Q, Yang Y, et al. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC)[J]. Diagn Pathol,2013,8:197..
[19]
Iftikhar R, Kladney RD, Havlioglu N, et al. Disease- and cell-specific expression of GP73 in human liver disease[J]. Am J Gastroenterol, 2004,99(6):1087-1095.
[20]
Qiao Y, Chen J, Li X, et al. Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection[J]. Clin Biochem,2014,47(16-17):216-222.
[21]
Wei H, Zhang J, Li H, et al. GP73, a new marker for diagnosing HBV-ACLF in population with chronic HBV infections[J]. Diagn Microbiol Infect Dis,2014,79(1):19-24.
[22]
Wang F, Li Z, Li L, et al. GP73 was upregulated in PBMC stimulated with ConA but failed to promote lymphocyte proliferation[J]. Cell Biol Int,2015,39(3):334-340.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(11): 1089-1091.
[2] 崔玉峰, 林毅军, 王志民. 幽门螺杆菌分子检测技术研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 257-262.
[3] 唐金侨, 叶宇佳, 王港, 赵彬, 马艳宁. 医学影像学检查方法在颞下颌关节紊乱病中临床应用研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 406-411.
[4] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 熊鹰, 林敬莱, 白奇, 郭剑明, 王烁. 肾癌自动化病理诊断：AI离临床还有多远？[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 535-540.
[7] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[8] 郑大雯, 王健东. 胆囊癌辅助诊断研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 769-773.
[9] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[10] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[11] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[14] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[15] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？